Results 11 to 20 of about 50,558 (217)

Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data

Drugs in Context, 2023
Background: Nirmatrelvir/ritonavir is authorized for the treatment of COVID-19 but has several contraindications and potential drug–drug interactions (pDDIs) due to ritonavir-induced irreversible inhibition of cytochrome P450 3A4.
Christoph Lübbert, Igor Dykukha, Jann-Patrick Pelz, Helen Yearley, Wolfgang Junker, Nina Gruber, Sibyll Escher, Katrin Biereth, Sima Melnik, Julia Puschmann   +9 more
doaj   +2 more sources

Influence of Carrier (Polymer) Type and Drug-Carrier Ratio in the Development of Amorphous Dispersions for Solubility and Permeability Enhancement of Ritonavir [PDF]

Journal of Excipients and Food Chemicals, 2017
The influence of the ratio of Eudragit® L100-55 or Kolliphor® P188 on the solubility, dissolution, and permeability of ritonavir was studied with a goal of preparing solid dispersions (SDs) of ritonavir.
Vivek S. Dave, Nishikant A. Raut, Deepak Gupta, Suprit D. Saoji, Pradip W. Dhore   +4 more
doaj   +3 more sources

Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19

Immunity, Inflammation and Disease
Background and Aim Simnotrelvir/ritonavir and nirmatrelvir/ritonavir are major treatments for COVID‐19, but their comparative efficacy and safety, especially in patients with moderate to severe COVID‐19, remain unclear.
Xin Chen, Xiao‐Qing Lin, Fang Cheng, Shi‐Lin Zheng, Qiang Zhang, Te Wu, Xian‐Gao Jiang, Ji‐Chan Shi   +7 more
doaj   +2 more sources

Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID-19: A Systematic Review and Meta-Analysis of Retrospective Studies. [PDF]

Health Sci Rep
ABSTRACT Background and Aim Nirmatrelvir/ritonavir (Paxlovid) and remdesivir are antiviral agents that have been widely used in the management of patients with Coronavirus disease 2019 (COVID‐19). This systematic review and meta‐analysis were conducted to compare the clinical effectiveness and safety outcomes of Paxlovid and remdesivir among patients ...
Akbarzadeh A, Razeghian M, Hajiabadi F, Dehghan P, Ahmadi-Mazhin S, Eshaghzadeh M, Poursadeqiyan M, Shabestan R.   +7 more
europepmc   +2 more sources

Ritonavir Form III: Lightning strikes twice at the same time, 137 miles apart [PDF]

, 2022
Polymorph screening is a crucial step in the characterization and development of pharmaceuticals. The 1998 recall of ritonavir upon the unexpected appearance of the more stable Form II polymorph remains a notorious case of disappearing polymorphs as the ...
Daniel, Smith, Stephen, Byrn, Jordan, Croom, Larry, Chan, Susan, Bogdanowich-Knipp, Haley, Bauser, Stephan, Parent, Dale, Purcell, Ami, Bhavsar, Adrian, Radocea, Pamela, Smith, Andrew, McCalip   +11 more
core   +2 more sources

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Awareness on current status of usage of ritonavir in the management of covid among dental students

Journal of Advanced Pharmaceutical Technology & Research, 2022
Ritonavir's pharmacodynamics raise questions regarding whether medication concentrations high enough to block the SARS-CoV-2 proteases can be obtained. Ritonavir may have a therapeutic benefit at any stage of the disease, although pharmacodynamic issues ...
Jagadheeswari Ramamoorthy, Dhanraj Ganapathy, Kiran Kumar Pandurangan, Nabeel Ahmed, Subhabrata Maiti   +4 more
doaj   +1 more source

Scutellaria baicalensis decreases ritonavir-induced nausea

AIDS Research and Therapy, 2005
Background Protease inhibitors, particularly ritonavir, causes significant gastrointestinal disturbances such as nausea, even at low doses. This ritonavir-induced nausea could be related to its oxidative stress in the gut.
Chang Wei-Tien, Mehendale Sangeeta, Aung Han, Wang Chong-Zhi, Xie Jing-Tian, Yuan Chun-Su   +5 more
doaj   +1 more source

Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study. [PDF]

, 2015
Increased levels of markers of systemic inflammation have been associated with serious non-AIDS events even in patients on fully suppressive antiretroviral therapy.
Richard Gilson, McKendry, A, Gilson, R, Ana Milinkovic, Arenas-Pinto, A, Maini, M, Milinkovic, A, Anna McKendry, Peppa, D, Alejandro Arenas-Pinto, Dimitra Peppa, Mala Maini   +11 more
core   +2 more sources

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice

, 2023
Nirmatrelvir/ritonavir (Paxlovid) is indicated in patients who are at high risk of progressing to severe COVID-19. Many of these patients are concomitantly prescribed various medications for other indications. Ritonavir has no activity against SARS-CoV-2,
Magdalena Niedzielko, Dagmara Mirowska-Guzel, Rafał Kułakowski   +2 more
core   +1 more source